Company Overview and News
Ameriprise Financial, Inc. (AMP - Free Report) is scheduled to report first-quarter 2018 results on Apr 23, after the market closes. Its earnings and revenues in the quarter are expected to grow year over year. Last quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from an improvement in revenues. Also, growth in assets under management (AUM) and assets under administration (AUA) were on the positive side.
Most banks that reported first-quarter 2018 results this week managed to record bottom-line improvement on the back of rising rates, lower taxes and improved trading activities. This also led to positive price movement for most bank stocks over the last five trading days. In addition to the benefits from higher interest rates, banks’ results mirrored a marginal upswing in loans. Moreover, the results show eased margin pressure.
Zions Bancorporation (ZION - Free Report) is scheduled to announce first-quarter 2018 results on Apr 23, after market close. Its revenues and earnings for the quarter are projected to grow year over year. Last quarter, Zions’ earnings outpaced the Zacks Consensus Estimate. Higher revenues and benefit from provisions aided results. However, higher adjusted non-interest expenses was the undermining factor.
Stocks opened slightly higher on Wednesday as investors begin to reap some rewards from the start of first quarter earnings season. Despite this recent market momentum, uncertainty is still present, which means investors need to continue to utilize Q1 earnings season in order to look for stocks set to top earnings estimates.
Discover Financial Services (DFS) saw favorable momentum in its business in fiscal 2017 and in 4Q17. According to the company’s management, the momentum would also be visible in 2018, which could help the company in terms of return on equity (or ROE) as well as growth. Additionally, this momentum could prove beneficial for its shareholders.
Amazon (AMZN) is exploring launching a banking service that would appeal to young people and those without traditional bank accounts, according to recent reports by The Wall Street Journal and Bloomberg. The reports about Amazon venturing into the banking business, most likely with a checking account product, came a few months after Amazon, JPMorgan Chase (JPM), and Berkshire Hathaway (BRK.A) (BRK.
I’ve been calling a bitcoin bubble for some time now and admittedly I haven’t been right yet. In fact, the bitcoin price today is above $8,000, for the first time in a month — an increase that some analysts are labeling “bizarre“.
NEW YORK (Reuters) - Quirks in the new U.S. tax code are sowing doubts over how much big banks can boost dividends and stock buybacks this year, threatening to take the shine off what are likely to be strong quarterly profits.
Over the last four trading days, performance of banking stocks has been encouraging. Easing U.S.-China trade war tension has provided some respite to investors, infusing overall positivity in the market. Mortgage rates declined this week, hitting 4.4%, along with bond yields, on fears of a trade war. Despite this, investors are apprehensive about parking funds in the housing market, thanks to the volatility in the financial world.
The stock market has bounced almost 1,000 Dow points from its lows on Wednesday morning as the fears of trade wars and runaway interest rates start to ease. It turns out that investors are flocking back into bank stocks, and analysts are deciding that there finally may be room for more of a risk-on trade than what was feared on Wednesday morning.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET